Zeki Toprak1, Egemen Cebeci2, Serife Aysen Helvaci3, Ilkim Deniz Toprak3, Yasin Kutlu3, Abdullah Sakin4, Tufan Tukek3. 1. Department of Internal Medicine, Okmeydani Training and Research Hospital, Istanbul, Turkey. zktprk@gmail.com. 2. Department of Nephrology, Okmeydani Training and Research Hospital, Istanbul, Turkey. 3. Department of Internal Medicine, Okmeydani Training and Research Hospital, Istanbul, Turkey. 4. Department of Medical Oncology, Okmeydani Training and Research Hospital, Istanbul, Turkey.
Abstract
PURPOSE: Cisplatin is a chemotherapeutic agent with potential nephrotoxicity. Delayed increase in serum creatinine after cisplatin administration shows that serum creatinine may not be a sufficient marker for early detection of nephrotoxicity. Urinary insulin-like growth factor binding protein-7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 (TIMP-2) which are cell-cycle arrest biomarkers have been proposed recently for early detection of acute kidney injury (AKI). Herein, we evaluated urinary TIMP-2/IGFBP7 levels before and after cisplatin administration to patients with lung cancer and their role was examined in the early diagnosis of AKI. METHODS: Patients with glomerular filtration rate above 60 mL/min who had cisplatin treatment were enrolled. Urinary TIMP-2/IGFBP7 and serum creatinine levels were measured before and at 24th hour after cisplatin administration. Serum creatinine level was also measured at 48th hour after treatment. RESULTS: Cisplatin-associated AKI was detected in 13 patients (28%) among the 45 patients enrolled. There was no difference between creatinine, IGFBP7 and (IGFBP7 × TIMP-2)/1000 levels before and after treatment; urinary TIMP-2 level at 24th hour was significantly higher than the level before the treatment (p = 0.02). (IGFBP7 × TIMP-2)/1000 values were not different between patients with or without AKI. The area under the curve of (IGFBP7 × TIMP-2)/1000 at 24th hour of the treatment was 0.46 (CI 0.26-0.67). CONCLUSION: Although urinary IGFBP7 and TIMP-2 levels are used as biomarkers for early detection of AKI for patients in intensive care units and after surgery, they seem not to be useful for early detection of AKI due to cisplatin.
PURPOSE:Cisplatin is a chemotherapeutic agent with potential nephrotoxicity. Delayed increase in serum creatinine after cisplatin administration shows that serum creatinine may not be a sufficient marker for early detection of nephrotoxicity. Urinary insulin-like growth factor binding protein-7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 (TIMP-2) which are cell-cycle arrest biomarkers have been proposed recently for early detection of acute kidney injury (AKI). Herein, we evaluated urinary TIMP-2/IGFBP7 levels before and after cisplatin administration to patients with lung cancer and their role was examined in the early diagnosis of AKI. METHODS:Patients with glomerular filtration rate above 60 mL/min who had cisplatin treatment were enrolled. Urinary TIMP-2/IGFBP7 and serum creatinine levels were measured before and at 24th hour after cisplatin administration. Serum creatinine level was also measured at 48th hour after treatment. RESULTS:Cisplatin-associated AKI was detected in 13 patients (28%) among the 45 patients enrolled. There was no difference between creatinine, IGFBP7 and (IGFBP7 × TIMP-2)/1000 levels before and after treatment; urinary TIMP-2 level at 24th hour was significantly higher than the level before the treatment (p = 0.02). (IGFBP7 × TIMP-2)/1000 values were not different between patients with or without AKI. The area under the curve of (IGFBP7 × TIMP-2)/1000 at 24th hour of the treatment was 0.46 (CI 0.26-0.67). CONCLUSION: Although urinary IGFBP7 and TIMP-2 levels are used as biomarkers for early detection of AKI for patients in intensive care units and after surgery, they seem not to be useful for early detection of AKI due to cisplatin.
Authors: Sarah Faubel; Eli C Lewis; Leonid Reznikov; Danica Ljubanovic; Thomas S Hoke; Hilary Somerset; Dong-Jin Oh; Lawrence Lu; Christina L Klein; Charles A Dinarello; Charles L Edelstein Journal: J Pharmacol Exp Ther Date: 2007-03-30 Impact factor: 4.030
Authors: Jay L Koyner; Andrew D Shaw; Lakhmir S Chawla; Eric A J Hoste; Azra Bihorac; Kianoush Kashani; Michael Haase; Jing Shi; John A Kellum Journal: J Am Soc Nephrol Date: 2014-12-22 Impact factor: 10.121
Authors: Martin Kimmel; Jing Shi; Joerg Latus; Christoph Wasser; Daniel Kitterer; Niko Braun; Mark Dominik Alscher Journal: Clin J Am Soc Nephrol Date: 2016-03-29 Impact factor: 8.237
Authors: Melanie Meersch; Christoph Schmidt; Hugo Van Aken; Sven Martens; Jan Rossaint; Kai Singbartl; Dennis Görlich; John A Kellum; Alexander Zarbock Journal: PLoS One Date: 2014-03-27 Impact factor: 3.240
Authors: Kianoush Kashani; Ali Al-Khafaji; Thomas Ardiles; Antonio Artigas; Sean M Bagshaw; Max Bell; Azra Bihorac; Robert Birkhahn; Cynthia M Cely; Lakhmir S Chawla; Danielle L Davison; Thorsten Feldkamp; Lui G Forni; Michelle Ng Gong; Kyle J Gunnerson; Michael Haase; James Hackett; Patrick M Honore; Eric A J Hoste; Olivier Joannes-Boyau; Michael Joannidis; Patrick Kim; Jay L Koyner; Daniel T Laskowitz; Matthew E Lissauer; Gernot Marx; Peter A McCullough; Scott Mullaney; Marlies Ostermann; Thomas Rimmelé; Nathan I Shapiro; Andrew D Shaw; Jing Shi; Amy M Sprague; Jean-Louis Vincent; Christophe Vinsonneau; Ludwig Wagner; Michael G Walker; R Gentry Wilkerson; Kai Zacharowski; John A Kellum Journal: Crit Care Date: 2013-02-06 Impact factor: 9.097
Authors: Federico Nalesso; Leda Cattarin; Laura Gobbi; Antonio Fragasso; Francesco Garzotto; Lorenzo Arcangelo Calò Journal: Int J Nephrol Renovasc Dis Date: 2020-04-24